Stock Report: Eli Lilly & Co. (LLY) Report Updated: May 20, 2013 | Print This Page

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s neuroscience products treat schizophrenia, mixed/manic episodes, and bipolar maintenance; depression, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; attention-deficit hyperactivity disorders; obsessive-compulsive and panic disorders, and bulimia nervosa; and bipolar and treatment-resistant depression. Its endocrinology products treat diabetes; type 2 diabetes; osteoporosis in postmenopausal women and men at high risk of fracture; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. The company’s oncology products treat malignant pleural mesothelioma; pancreatic, metastatic breast, non-small cell lung, ovarian, bladder, colorectal, and head and neck cancers, as well as cardiovascular products treat erectile dysfunction, benign prostatic hyperplasia, high cholesterol, pulmonary arterial hypertension; reduce thrombotic cardiovascular events; and used as adjunct to percutaneous coronary intervention. In addition, it provides animal health products, such as cattle feed additives; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; leanness and performance enhancers for swine and cattle; protein supplements to improve milk productivity in dairy cows; anticoccidial agents; antibiotics to control enteric infections in calves and swine; products to treat canine separation anxiety; products that prevent flea infestations on dogs, kills fleas, prevent heartworm disease, and control intestinal parasite infections; and other pharmaceutical products to treat staphylococcal and bacterial infections. The company distributes its products through independent wholesale distributors; and directly to pharmacies. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.